Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally...
Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also...
SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Gastric Cancer.
SEONGNAM, South Korea, Dec. 24, 2025 /PRNewswire/ -- SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101...
First The Generation Essentials Group-Sponsored SPAC Announces Successful Closing of $150 million IPO
PARIS, NEW YORK and LONDON, Dec. 23, 2025 /PRNewswire/ -- TGE Value Creative Solutions Corp (the "Company"), a special purpose acquisition company sponsored by The Generation Essentials Group (NYSE: TGE; LSE: TGE), announced today that it...
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC
SUZHOU, China, Dec. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio...
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
SAN FRANCISCO, Dec. 16, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 2563.HK), today announced that the first patient has been dosed for one of its key oversea...
Aspire Announces Major Australia, EU and US Regulatory Milestones, Marking a New Chapter in Its Global Expansion
SINGAPORE, Dec. 16, 2025 /PRNewswire/ -- Aspire, the Singapore-headquartered fintech, today announced a series of regulatory milestones marking a major step in its global expansion. Over the past year alone, the company has secured eight licenses...
Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of...
Zymedi Announces "rapaprutug" as the International Nonproprietary Name (INN) for ZMA001
INCHEON, South Korea, Dec. 8, 2025 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that the World Health Organization (WHO) has assigned rapaprutug as the International Nonproprietary Name (INN) for the company's first-in-class antibody therapy...
Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases. These awards across several geographies recognize the progress represented by Voranigo® for patients...